Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Teva
QuintilesIMS
Deloitte
Fuji
Express Scripts
Johnson and Johnson
Cantor Fitzgerald

Generated: May 27, 2018

DrugPatentWatch Database Preview

Zalcitabine - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for zalcitabine and what is the scope of zalcitabine freedom to operate?

Zalcitabine
is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for zalcitabine
Medical Subject Heading (MeSH) Categories for zalcitabine
Synonyms for zalcitabine
.beta.-D-2',3'-Dideoxycytidine
.beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
.beta.-D-DDC
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine
1-(2',3'-DIDEOXY-BETA-RIBOFURANOSYL)CYTOSINE
16803P
2,3-dideoxycytidine
2', 3'-dideoxycytidine
2',3-DIDEOXYCYTIDINE
2',3'-DIDEOXYCYTIDINE
2',3'-Dideoxycytidine & Interferon-alpha
2',3'-Dideoxycytidine & Interferon.alpha.
2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate)
2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
2',3'-Dideoxycytidine, >=98% (HPLC)
2',3'-Dideoxycytidine, >=99.0% (HPLC)
3-[(5S,2R)-5-(hydroxymethyl)oxolan-2-yl]-6-amino-3-hydropyrimidin-2-one
3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine
4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)TETRAHYDRO-2-FURANYL]-2(1H)-PYRIMIDINONE
4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
42060-EP2295503A1
42060-EP2298761A1
42060-EP2305695A2
42060-EP2305696A2
42060-EP2305697A2
42060-EP2305698A2
42060-EP2311808A1
42060-EP2311829A1
481D892
5-25-14-00313 (Beilstein Handbook Reference)
6L3XT8CB3I
7481-89-2
78798-EP2298783A1
78798-EP2305695A2
78798-EP2305696A2
78798-EP2305697A2
78798-EP2305698A2
AB0014137
AB01085
AB2000246
AC-824
AC1L2N6R
AJ-08916
AK-54661
AKOS015854844
AKOS015894505
AN-15472
ANW-36530
AOB5609
BC203863
BDBM50145605
BETA-D-2',3'-DIDEOXYCYTIDINE
Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
Beta-D-DDC
bmse000712
BPBio1_001378
BRN 0654956
BSPBio_001253
C07207
C9H13N3O3
CAS-7481-89-2
CCG-101050
CCRIS 692
CHEBI:10101
CHEMBL853
CPD000058253
CS-1110
Cytidine, 2',3'-dideoxy & Interferon alpha
Cytidine, 2',3'-dideoxy-
Cytidine, 2',3'-dideoxy- & Colony-stimulating factor
Cytidine, 2',3'-dideoxy- & Interferon.alpha.
Cytidine, 2',3'-dideoxy-& Colony-stimulating factor
D 5782
D00412
D0DC7N
D0M1YO
D0Z9QR
D3581
DB-019728
DB00943
ddC
ddC (Antiviral)
DDC (DDC)
ddC & GM-CSF
DdC & IFN-alpha
ddC & IFN.alpha.
DdC & Interferon alpha
ddC & Interferon.alpha.
ddC & NP (from PHCA or HSA)
ddC & sCD4
ddC|||2',3'-Dideoxycytidine
ddCyd
Dideoxycytidine
dideoxycytidine (DDC)
DS-4152 & ddC
DSSTox_CID_3747
DSSTox_GSID_23747
DSSTox_RID_77182
DTXSID0023747
EU-0100360
GTPL4828
HE002764
HIVID
Hivid (TN)
Hivid, Dideoxycytidine, NSC 606170, Zalcitabine
Hivid;Dideoxycytidine;NSC 606170
Hivid(TM)
HMS1548B19
HMS1571O15
HMS2051H18
HMS2090C12
HMS2098O15
HMS2236N08
HMS3261G21
HSDB 7156
HY-17392
Interferon AD + ddC
J-700276
K278
KS-00000MRJ
KS-1130
Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine
Lopac0_000360
LP00360
LS-1645
M-2084
MCULE-6071296177
MFCD00012188
MLS000069636
MLS000759540
MLS001055363
MLS001424210
MLS006011951
MolPort-002-885-873
MolPort-003-699-779
NC00300
NCGC00090705-01
NCGC00090705-02
NCGC00090705-03
NCGC00090705-05
NCGC00090705-06
NCGC00090705-07
NCGC00090705-08
NCGC00090705-09
NCGC00090705-10
NCGC00090705-11
NCGC00090705-13
NCGC00090705-15
NCGC00179242-01
NCGC00257202-01
NCGC00259204-01
NCGC00261045-01
NSC 606170
NSC-606170
NSC-759655
NSC606170
NSC759655
NU004538
PC-SOD & ddC
Pharmakon1600-01502360
Prestwick0_001037
Prestwick1_001037
Prestwick2_001037
Prestwick3_001037
Q-201941
Ro 24-2027/000
Ro-24-2027/000
Ro-24-2027000
Ro-242027000
Ro-242027000/Ro-24-2027-000
RTC-064018
s1719
SAM001246779
SBB066036
SC-09165
SCHEMBL3598
SMR000058253
SPBio_003104
SRI-7707
SRI-7707_15
SRI-7707_17
SRI-7707-13
SRI-7707-14
ST069364
ST24043185
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
TC-064018
TimTec1_004969
Tox21_113491
Tox21_113491_1
Tox21_201655
Tox21_303169
Tox21_500360
UNII-6L3XT8CB3I
UPCMLD-DP115
UPCMLD-DP115:001
WREGKURFCTUGRC-POYBYMJQSA-N
Z1550648753
Zalcitabine (JAN/USP/INN)
Zalcitabine [USAN:INN:BAN]
Zalcitabine [USAN:USP:INN:BAN]
Zalcitabine, 2'3'-Dideoxycytidine
Zalcitabine, United States Pharmacopeia (USP) Reference Standard
Zalcitibine
ZB001188
ZINC39906

US Patents and Regulatory Information for zalcitabine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche HIVID zalcitabine TABLET;ORAL 020199-002 Jun 19, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche HIVID zalcitabine TABLET;ORAL 020199-001 Jun 19, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for zalcitabine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche HIVID zalcitabine TABLET;ORAL 020199-002 Jun 19, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Roche HIVID zalcitabine TABLET;ORAL 020199-001 Jun 19, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Roche HIVID zalcitabine TABLET;ORAL 020199-002 Jun 19, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Roche HIVID zalcitabine TABLET;ORAL 020199-001 Jun 19, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Deloitte
US Army
Daiichi Sankyo
Cantor Fitzgerald
QuintilesIMS
Johnson and Johnson
Medtronic
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.